Gene Editing Pioneer Editas Medicine Takes Center Stage
On October 1, 2024, Editas Medicine’s CFO Erick Lucera and VP of Corporate Communications and IR Cristi Barnett sat down with biotech analyst Geulah Livshits at Chardan’s 8th Annual Genetic Medicines Conference. As the discussion commenced, Geulah invited the duo to provide an overview of Editas’ groundbreaking platform and programs, as well as highlight key catalysts for the remainder of the year.
Erick Lucera began by expressing his gratitude for the opportunity to share Editas’ story. As a gene editing company born out of the Harvard-MIT Broad Institute, Editas boasts an impressive portfolio of foundational patents for the Cas9 and Cas12 enzymes, granting them unparalleled flexibility across the gene editing spectrum. Founded a decade ago and publicly traded since 2018, Editas has reached a pivotal moment in its history, marked by the achievement of human data for its revolutionary reni-cel product, designed to combat sickle cell disease.
What sets reni-cel apart is its autologous, personalized approach, tailored to individual patients. However, Editas is now poised to expand into the realm of in vivo gene editing, a breakthrough that promises to democratize access to this innovative technology, making it possible to reach a vastly broader patient population. According to Lucera, this development has the potential to be one of the most transformative moments in medical history.
Leave a Reply